Quiz › question 9 of 12 · First-line ART

Which is required before starting dolutegravir/lamivudine as first-line therapy?

A CD4 above 500 B Exclusion of lamivudine and integrase resistance, HBV, and viral load < 500,000 C A trial of three-drug therapy first D Genotypic tropism testing
Correct. Dovato is licensed only without known or suspected resistance to the integrase class or lamivudine. BHIVA adds a baseline viral load below 500,000 copies/mL and no need for tenofovir for hepatitis B.
Dovato SmPC §4.1BHIVA ART 2025 §5
Open the related case in the decision tool ← Previous Next question →